These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
225 related articles for article (PubMed ID: 22382501)
1. Pharmacogenomics of Cardiovascular Drugs for Atherothrombotic, Thromboembolic and Atherosclerotic Risk. Mauriello A; Ascrizzi A; Molinari R; Falco L; Caturano A; D'Andrea A; Russo V Genes (Basel); 2023 Nov; 14(11):. PubMed ID: 38003001 [TBL] [Abstract][Full Text] [Related]
2. Cardiovascular pharmacogenomics: the future of cardiovascular therapeutics? Roden DM Can J Cardiol; 2013 Jan; 29(1):58-66. PubMed ID: 23200096 [TBL] [Abstract][Full Text] [Related]
3. Pharmacogenomics: the genetics of variable drug responses. Roden DM; Wilke RA; Kroemer HK; Stein CM Circulation; 2011 Apr; 123(15):1661-70. PubMed ID: 21502584 [No Abstract] [Full Text] [Related]
4. Pharmacogenomics in cardiovascular disorders: Steps in approaching personalized medicine in cardiovascular medicine. Barone C; Mousa SS; Mousa SA Pharmgenomics Pers Med; 2009; 2():59-67. PubMed ID: 23226035 [TBL] [Abstract][Full Text] [Related]
5. Pharmacogenomics: application to the management of cardiovascular disease. Johnson JA; Cavallari LH; Beitelshees AL; Lewis JP; Shuldiner AR; Roden DM Clin Pharmacol Ther; 2011 Oct; 90(4):519-31. PubMed ID: 21918509 [TBL] [Abstract][Full Text] [Related]
6. Statins significantly reduce mortality in patients receiving clopidogrel without affecting platelet activation and aggregation: a systematic review and meta-analysis. An K; Huang R; Tian S; Guo D; Wang J; Lin H; Wang S Lipids Health Dis; 2019 May; 18(1):121. PubMed ID: 31122249 [TBL] [Abstract][Full Text] [Related]
7. Discussing race-related limitations of genomic testing for colon cancer risk: implications for education and counseling. Butrick MN; Vanhusen L; Leventhal KG; Hooker GW; Nusbaum R; Peshkin BN; Salehizadeh Y; Pavlick J; Schwartz MD; Graves KD Soc Sci Med; 2014 Aug; 114():26-37. PubMed ID: 24908172 [TBL] [Abstract][Full Text] [Related]
8. Overview of high throughput sequencing technologies to elucidate molecular pathways in cardiovascular diseases. Churko JM; Mantalas GL; Snyder MP; Wu JC Circ Res; 2013 Jun; 112(12):1613-23. PubMed ID: 23743227 [TBL] [Abstract][Full Text] [Related]
9. Assessment of a pharmacogenomic marker panel in a polypharmacy population identified from electronic medical records. Oetjens MT; Denny JC; Ritchie MD; Gillani NB; Richardson DM; Restrepo NA; Pulley JM; Dilks HH; Basford MA; Bowton E; Masys DR; Wilke RA; Roden DM; Crawford DC Pharmacogenomics; 2013 May; 14(7):735-44. PubMed ID: 23651022 [TBL] [Abstract][Full Text] [Related]
11. Recent developments and future directions for the use of pharmacogenomics in cardiovascular disease treatments. Berinstein E; Levy A Expert Opin Drug Metab Toxicol; 2017 Sep; 13(9):973-983. PubMed ID: 28792790 [TBL] [Abstract][Full Text] [Related]
12. Evidence for Clinical Implementation of Pharmacogenomics in Cardiac Drugs. Kaufman AL; Spitz J; Jacobs M; Sorrentino M; Yuen S; Danahey K; Saner D; Klein TE; Altman RB; Ratain MJ; O'Donnell PH Mayo Clin Proc; 2015 Jun; 90(6):716-29. PubMed ID: 26046407 [TBL] [Abstract][Full Text] [Related]
15. Clinical utility of pharmacogenetic biomarkers in cardiovascular therapeutics: a challenge for clinical implementation. Ong FS; Deignan JL; Kuo JZ; Bernstein KE; Rotter JI; Grody WW; Das K Pharmacogenomics; 2012 Mar; 13(4):465-75. PubMed ID: 22380001 [TBL] [Abstract][Full Text] [Related]